Relmada Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Relmada Therapeutics

15/03/2024 20:32

* Relmada Therapeutics Inc  RLMD.OQ   RLMD.O  is expected
to show
no change in quarterly revenue when it reports  results on March
19 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Relmada Therapeutics Inc
is
for a loss of 83 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $6.75​, above​ its last closing price
of $5.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.91       -0.91      -0.73     Beat    20
 Jun. 30 2023  -0.90       -0.90      -0.84     Beat    6.3
 Mar. 31 2023  -0.91       -0.89      -0.87     Beat    2.2​
 Dec. 31 2022              -1.33      -1.41     Missed  -6.2
 ​​Sep.        -1.44       -1.45      -1.31     Beat    9.6
 30 2022                                                
 Jun. 30 2022  -1.29       -1.27      -1.33     Missed  -4.5​
 Mar. 31 2022  -1.24       -1.27      -1.40     Missed  -10.6
 Dec. 31 2021  -1.66       -1.83      -1.80     Beat    1.6
 This summary was machine generated March 15 at 20:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)